Journal of Clinical Oncology
Articles in this Issue
Multi-cohort validation of a semaphorin prognostic signature to identify an immune- excluded subtype and therapeutic sensitivity in lung adenocarcinoma.
e20016 Background: Semaphorins, classically implicated in axonal guidance, have increasingly recognized roles in tumor pro...
First-in-human in vivo CAR T-cell generation using a CD8-targeted lipid nanoparticle platform in relapsed/refractory B-cell lymphoma.
7014 Background: R/R B-cell lymphomas remain challenging despite advances in ex vivo CAR T-cell therapies, which are limit...
Neoadjuvant/adjuvant serplulimab vs. placebo combined with chemotherapy for PD-L1–positive gastric cancer: A randomized, double-blind, multicenter phase 3 study.
4009 Background: The addition of immune checkpoint inhibitors (ICIs) to chemotherapy (chemo) in the neoadjuvant/adjuvant s...
Household costs of breast cancer and coping mechanisms in Kenya: A case of Kenyatta National Hospital.
11051 Background: In 2020, cancer was the third leading cause of mortality in Kenya, with breast cancer the most prevalent...
Real-world safety of tarlatamab in patients receiving recent or concurrent CNS radiation.
e20126 Background: Tarlatamab, a delta-like ligand 3 (DLL3)-directed bispecific T-cell engager, has revolutionized the tre...
Association of genomic and clinical factors with outcomes with front-line chemoimmunotherapy in patients with advanced biliary tract cancer.
4135 Background: Anti-PD1/L1 therapy plus gemcitabine/cisplatin is standard first-line therapy in advanced biliary tract c...
Outcomes of endovascular embolization in cancer-associated gastrointestinal bleeding: A nationwide inpatient analysis.
e16340 Background: Advances in endovascular techniques have improved the technical success of embolization for gastrointes...
A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM / Alliance A032101).
5004 Background: Patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated continuously with testos...
Impact of PD-L1 and HPV biomarkers on immune checkpoint inhibitor efficacy in locally advanced HNSCC: A systematic review of randomized trials.
e18050 Background: The role of immune checkpoint inhibitors (ICIs) in locally advanced head and neck squamous cell carcino...
Pre-treatment circulating tumour DNA (ctDNA) to predict survival and aid decision-making in head and neck cancer patients: 5-year outcome analysis.
e18017 Background: HPV-associated (HPV+) head and neck squamous cell carcinoma (HNSCC) has a favourable prognosis compared...
Stable colorectal cancer burden in inflammatory bowel disease over a decade: Nationwide U.S. trend analysis, 2012–2022.
e15651 Background: Colorectal cancer (CRC) remains a significant long-term complication of inflammatory bowel disease (IBD...
Adjuvant sintilimab plus bevacizumab following curative resection of spontaneously ruptured hepatocellular carcinoma: A prospective exploratory phase II study (CLEAR-2).
TPS4254 Background: Spontaneous rupture of hepatocellular carcinoma (srHCC) is a life-threatening complication associated...
High-risk clinic follow-up after genetic counseling and testing: Uptake patterns and predictors from a tertiary cancer center.
e22541 Background: Patients undergoing genetic counseling (GC) and germline testing (gGT) for hereditary cancer (CA) risk...
Low-dose vs. standard-dose trastuzumab deruxtecan in north Indian patients: Balancing efficacy, toxicity, and cost.
e13028 Background: The median target exposure level of trastuzumab deruxtecan (TDxD) with standard dose is approximately 2...
Iopofosine I-131 after BTK inhibitors in Waldenström macroglobulinemia: CLOVER-WaM subgroup efficacy and safety.
7094 Background: Waldenström Macroglobulinemia (WM) remains incurable with current available therapeutic options. Treatmen...
First-line tivozanib in favorable- and very favorable–risk metastatic renal cell carcinoma: Real-world evidence from the TIVOREAL-SOGUG study.
4547 Background: The optimal first-line treatment for favorable-risk metastatic renal cell carcinoma (mRCC) remains debate...
The molecular landscape and clinical nomogram of cholangiocarcinoma harboring ESCAT I alterations.
4158 Background: Cholangiocarcinoma (CCA) is the second most common primary liver cancer, with rising global incidence and...
Phase II clinical study of the efficacy and safety of adebrelimab in combination with lenvatinib as second-line treatment for advanced intrahepatic cholangiocarcinoma: Updated results.
e16162 Background: Advanced intrahepatic cholangiocarcinoma (ICC) carries a dismal prognosis, with limited second-line opt...
Onvansertib plus standard-of-care chemotherapy plus bevacizumab in first-line RAS-mutated metastatic colorectal cancer (mCRC): Interim results from the phase 2 randomized CRDF-004 trial.
3510 Background: Patients with RAS-mutated mCRC have limited treatment options. Chemotherapy in combination with bevacizum...
Projecting 2050 oncology workforce through historical regional trends and economic stratification.
9004 Background: Global oncology workforce planning increasingly relies on predictive modeling to guide policy and investm...
Phase Ib study of POLQ inhibitor SYN818 combined with olaparib in advanced solid tumors.
TPS3181 Background: SYN818 is a selective, potent oral POLQ helicase inhibitor. POLQ is essential for microhomology-mediat...
Mandibular preservation with neoadjuvant tislelizumab plus platinum-doublet chemotherapy in locally advanced resectable oral squamous cell carcinoma: A prospective phase II trial.
6090 Background: Segmental mandibulectomy for locally advanced oral squamous cell carcinoma (OSCC) severely compromises qu...
First-line immune checkpoint inhibitors in elderly colorectal cancer patients in the real world: Retrospective phase of the multicenter ELDER CRC trial.
3539 Background: dMMR/MSI-H metastatic colorectal cancer (mCRC) is more common among the elderly. However, insufficient da...
Preliminary results of safety and antitumor activity from a first-in-human phase 1 study of AWT020, a bifunctional anti–PD-1/IL-2 fusion protein, in patients with advanced tumors.
2528 Background: Immune checkpoint inhibitors have transformed treatment landscape across multiple cancer types, however,...
Language use and its relationship to patient experience and treatment compliance in genitourinary oncology.
e23254 Background: Disparities associated to language in cancer care are well-documented however inadequately defined in g...